ATCC

CELL PANEL



BREAST CANCER BIOMARKERS CELL LINE PANEL 1

The Breast Cancer Biomarkers Cell Line Panel 1 (ATCC® TCP-1004™) comprises 7 tumor cell lines isolated from a variety of primary and metastatic sites, and annotated with pre-operative chemotherapy treatments and published positive and negative biomarkers. The table below provides more information for the cell lines included in this panel.

ATCC® No.	Designation	Pathology	Site of Isolation	Age (years)	Positive Markers [1,2,3]	Negative Markers [1,2,3,4,5,6,7]	Other significant features	Patient Treatment [1]
CRL-1897™	UACC-812	Infiltrating ductal carcinoma	Breast	43	HER-2/neu	ER, PR, EGFR, P-glycoprotein		Vinblastine, Adriamycin, Cytoxan, Cyclophosphamide, Methotrexate, 5-fluorouracil
CRL-1902™	UACC-893	Infiltrating ductal carcinoma	Breast	57	HER-2/neu	ER, PR, EGFR, P-glycoprotein, MASPIN	MASPIN promoter methylation has been reported for this line.[5]	None
CRL-2983™	UACC-3199	Infiltrating ductal carcinoma	Axillary nodes	58	EGFR	ER, PR, HER-2/neu	Methylated BRCA-1 promoter	Cytoxan, Adriamycin, 5-fluorouracil, Tamoxifen, Mitoxantrone, Vinblastine
CRL-2988™	UACC-3133	Poorly differentiated adenocarci-noma and lobular carcinoma	Pleural fluid	63	HER-2/neu, BMP-3	ER (very low), PR, EFGR, MASPIN, DSC3, BMP-2	MASPIN promoter methylation has been reported for this line.[5]	Surgery only
CRL-3127™	UACC-1179	Adenocarcinoma	Pleural fluid	62	HER-2/neu	ER, PR, EFGR, MASPIN, DSC3	p53 R213X mutation and MASPIN promoter methylation have been reported for this line.[5,8]	Adriamycin, Cytoxan, Methotrexate, Tamoxifen
CRL-3166™	UACC-732	Adenocarcinoma	Pleural fluid	35	HER-2/neu, PR	ER, EGFR	Drug resistant cell line to cyclin D kinase 4/6 inhibitor and HER-2 inhibitors.[9]	Vinblastine, Adriamycin, Cytoxan
CRL-3180™	UACC-2087	Adenocarcinoma	Pleural fluid	53	EGFR	ER, PR, HER-2/neu, vimentin, MASPIN, DSC3	p53V216M mutation has been reported in this cell line. It has also been reported that the MASPIN promoter is not methylated.[5,10]	Cyclophosphamide, Methotrexate, 5-fluorouracil, Thymidine phophorylase, Tamoxifen

REFERENCES

1 Robey IF, et al. Regulation of the Warburg Effect in Early-Passage Breast Cancer Cells. Neoplasia. 10(8):745-56, 2008. PubMed: 18670636

2 Alarmo EL, et al. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res Treat. 103(2):239-46, 2007. PubMed: 17004110

3 Ketolainen JM, et al. Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Res Treat 124(2):377:86, 2010. PubMed:20182795

4 Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed:1674877

5 Esteller, M. Cancer Metastasis - Biology and Treatment: DNA Methylation, Epigenetics and Metastasis. Springer. AA Dordrecht, The Netherlands. 2005. pp.142-43.

6 Domann FE, et al. Epigentic silencing of maspin gene expression in human breast cancers. Int J Cancer. 85(6):805-10, 2000. PubMed: 10709100

7 Oshiro MM, et al. Epigentic silencing of DSC3 is a common event in human breast cancer. Breast Cancer Res. 7(5):R669-80, 2005. PubMed:16168112

8 Oshiro MM, et al. Mutant p53 and aberrant cytosine methylation cooperate to silence gene expression. Oncogene. 22(23):3624-34,2003. PubMed:12789271

9 Finn RS, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11(5):R77, 2009. PubMed:19874578

10 Watts GS, et al. The acetyletransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia. 6(3): 187-94, 2004. PubMed: 151533330

11 Rice JC, et al. Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypocetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res. 28(17):3233-3239, 2000. PubMed: 10954590

10801 University Boulevard
Manassas, Virginia 20110-2209

703.365.2700 703.365.2701 sales@atcc.org www.atcc.org

CB-122021-v02